A 2-year Study to Evaluate the Onset of Action of Cladribine Tablets in Subjects with Highly Active Relapsing Multiple Sclerosis: Results from MAGNIFY- MS Baseline Analysis

被引：0

作者：

De Stefano, N. ^{[1
]}

Achiron, A. ^{[2
]}

Barkhof, F. ^{[3
]}

Chan, A. ^{[4
]}

Derfuss, T. ^{[5
]}

Hodgkinson, S. ^{[6
]}

Leocani, L. ^{[7
]}

Montalbant, X. ^{[8
]}

Pratt, A. ^{[9
]}

Schmierer, K. ^{[10
]}

Sellebjerg, F. ^{[11
]}

Vermersch, P. ^{[12
]}

Wiendl, H. ^{[13
]}

Keller, B. ^{[14
]}

Roy, S. ^{[15
]}

机构：

[1] Univ Siena, Dept Neurol & Behav Sci, Siena, Italy

[2] Sheba Acad Med Ctr, Multiple Sclerosis Ctr, Ramat Gan, Israel

[3] Vrije Univ Amsterdam Med Ctr, Dept Radiol, Amsterdam, Netherlands

[4] Univ Bern, Univ Hosp Berne, Bern, Switzerland

[5] Univ Hosp Basel, Dept Neurol, Basel, Switzerland

[6] Univ New South Wales Med, Ingham Inst Appl Med Res, Sydney, NSW, Australia

[7] Univ Vita Salute San Raffaele, Expt Neurophysiol Unit, Milan, Italy

[8] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada

[9] Univ Montreal, Dept Neurosci, Montreal, PQ, Canada

[10] Queen Mary Univ London, Blizard Inst Neurosci, Barts & London Sch Med & Dent, London, England

[11] Univ Copenhagen, Rigshosp, Danish MS Ctr, Copenhagen, Denmark

[12] Univ Lille, INSERM, U1172, FHU Imminent,CHU Lille, Lille, France

[13] Univ Munster, Dept Neurol, Inst Translat Neurol, Munster, Germany

[14] Merck KGaA, Darmstadt, Germany

[15] Merck, Aubonne, Switzerland

来源：

EUROPEAN JOURNAL OF NEUROLOGY | 2020年 / 27卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

EPO1262

引用

页码：685 / 686

页数：2

共 50 条

[1] A 2-year Study to Evaluate the Onset of Action of Cladribine Tablets in Subjects with Highly Active Relapsing Multiple Sclerosis: Results from MAGNIFY-MS Baseline Analysis
De Stefano, Nicola
Achiron, Anat
Barkhof, Frederik
Chan, Andrew
Derfuss, Tobias
Hodgkinson, Suzanne
Leocani, Letizia
Montalban, Xavier
Prat, Alexandre
Schmierer, Klaus
Sellebjerg, Finn
Vermersch, Patrick
Wiendl, Heinz
Keller, Birgit
Roy, Sanjeev
NEUROLOGY, 2020, 94 (15)
[2] Early Onset of Action and Sustained Efficacy of MRI Outcomes During Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis: Results of the 2-year MAGNIFY-MS Study
De Stefano, Nicola
Achiron, Anat
Barkhof, Frederik
Chan, Andrew
Derfuss, Tobias
Hodgkinson, Suzanne
Leocani, Letizia
Montalban, Xavier
Prat, Alexandre
Schmierer, Klaus
Sellebjerg, Finn
Vermersch, Patrick
Wiendl, Heinz
Keller, Birgit
Smyk, Andrzej
Gardner, Lidia
NEUROLOGY, 2023, 100 (17)
[3] Early onset of action and sustained efficacy of MRI outcomes during cladribine tablets treatment in highly active relapsing multiple sclerosis: results of the 2-year MAGNIFY-MS study
De Stefano, N.
Achiron, A.
Barkhof, F.
Chan, A.
Derfuss, T.
Hodgkinson, S.
Leocani, L.
Montalban, X.
Prat, A.
Schmierer, K.
Sellebjerg, F.
Vermersch, P.
Wiendl, H.
Keller, B.
Smyk, A.
Gardner, L.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 629 - 631
[4] Blood Biomarker Dynamics in Highly Active Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study
Wiendl, Heinz
De Stefano, Nicola
Barkhof, Frederik
Montalban, Xavier
Achiron, Anat
Derfuss, Tobias
Chan, Andrew
Hodgkinson, Suzanne
Prat, Alexandre
Leocani, Letizia
Schmierer, Klaus
Sellebjerg, Finn
Vermersch, Patrick
Jin, Hulin
Jarvinen, Elina
Chudecka, Anita
Gardner, Lidia
NEUROLOGY, 2023, 100 (17)
[5] Blood Biomarker Dynamics in Highly Active Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study
Wiendl, H.
De Stefano, N.
Barkhof, F.
Montalban, X.
Achiron, A.
Derfuss, T.
Chan, A.
Hodgkinson, S.
Prat, A.
Leocani, L.
Schmierer, K.
Sellebjerg, F.
Vermersch, P.
Jin, H.
Jaervinen, E.
Chudecka, A.
Gardner, L.
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 21 - 22
[6] Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study
Wiendl, Heinz
Barkhof, Frederik
Montalban, Xavier
Achiron, Anat
Derfuss, Tobias
Chan, Andrew
Hodgkinson, Suzanne
Prat, Alexandre
Leocani, Letizia
Schmierer, Klaus
Sellebjerg, Finn
Vermersch, Patrick
Jin, Hulin
Chudecka, Anita
Kloetgen, Andreas
Lin, Dongdong
Gardner, Lidia
De Stefano, Nicola
FRONTIERS IN IMMUNOLOGY, 2025, 16
[7] Stabilization of Cognitive Function in Patients With Highly Active Relapsing Multiple Sclerosis Treated With Cladribine Tablets During the 2-Year CLARIFY-MS study
Langdon, D.
Brochet, B.
Havrdova, E. K.
Lechner-Scott, J.
Montalban, X.
Patti, F.
Piehl, F.
Selmaj, K.
Solari, A.
Alexandri, N.
Nolting, A.
Lehn, A.
Smyk, A.
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 60 - 61
[8] Reduction in cua mri lesions in the first 6 months of cladribine tablets treatment for highly active relapsing multiple sclerosis: magnify-ms study
De Stefano, N.
Barkhof, F.
Montalban, X.
Achiron, A.
Derfuss, T.
Chan, A.
Hodgkinson, S.
Prat, A.
Leocani, L.
Schmierer, K.
Sellebjerg, F.
Vermersch, P.
Wiendl, H.
Keller, B.
Roy, S.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 303 - 303
[9] Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis MAGNIFY-MS
de Stefano, Nicola
Barkhof, Frederik
Montalban, Xavier
Achiron, Anat
Derfuss, Tobias
Chan, Andrew
Hodgkinson, Suzanne
Prat, Alexandre
Leocani, Letizia
Schmierer, Klaus
Sellebjerg, Finn
Vermersch, Patrick
Wiendl, Heinz
Keller, Birgit
Roy, Sanjeev
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2022, 9 (04): : E1187
[10] Long-term effectiveness of cladribine tablets over 4 years in relapsing multiple sclerosis: Results from the MAGNIFY-MS Extension study
De Stefano, Nicola
Vermersch, Patrick
Wiendl, Heinz
Barkhof, Frederik
Montalban, Xavier
Achiron, Anat
Derfuss, Tobias
Chan, Andrew
Prat, Alexandre
Leocani, Letizia
Schmierer, Klaus
Sellebjerg, Finn
Lehn, Annette
Smyk, Andrzej
Nolting, Axel
Koelbach, Ralf
Hodgkinson, Suzanne
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 374 - 376

← 1 2 3 4 5 →